ASH 2018 Annual Meeting Highlights in MDS


Combination of Pracinostat and Azacitidine in Patients with High/Very High-Risk MDS
– Ehab Atallah, MD

Run Time: 04:37

Begin


Nivolumab or Ipilimumab with or without Azacitidine for Patients with MDS
– Guillermo Garcia-Manero, MD

Run Time: 02:35

Begin


Double Immune Checkpoint Inhibition in Patients with MDS
– Guillermo Garcia-Manero, MD

Run Time: 02:00

Begin


Safety and Efficacy of Deferasirox Vs. Placebo in Iron-Overloaded Patients with Low- and Intermediate-1-Risk MDS
– Guillermo Garcia-Manero, MD

Run Time: 02:19

Begin


Initial Results of a Phase 1/2 Study of Tomaralimab for Patients with Low-risk MDS
– Guillermo Garcia-Manero, MD

Run Time: 02:17

Begin


Oral Rigosertib Combined with Azacitidine in Patients with Higher-Risk MDS
– Shyamala C. Navada, MD, MSCR

Run Time: 06:52

Begin


The MEDALIST Trial of Luspatercept in Patients with Very Low-, Low-, or Intermediate-Risk MDS
– David P. Steensma, MD, FACP

Run Time: 03:23

Begin


Factors Associated with Early Therapy Initiation in Patients with MDS
– David P. Steensma, MD, FACP

Run Time: 03:29

Begin


Update on the Imetelstat Clinical Trial in MDS
– David P. Steensma, MD, FACP

Run Time: 04:40

Begin


Ivosidenib Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant R/R MDS
– Eytan M. Stein, MD

Run Time: 02:46

Begin


Selinexor Is Efficacious and Tolerable in Patients with MDS Refractory to HMAs
– Eytan M. Stein, MD

Run Time: 02:12

Begin